1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - For individual participant data meta-analysis.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [thanima1221@gmail.com].
   


6. For how long will this data be available start date provided 04-12-2024 and end date provided 04-12-2025?
   Response - Immediately following publication. No end date.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Aim: The aim of this in vivo study was to compare the efficacy of three desensitizing agents in reducing dentinal hypersensitivity. The investigation focused on assessing the immediate and lasting effects of the three agents on alleviating discomfort associated with dentinal hypersensitivity.

Methods: A randomized controlled trial was conducted on a cohort of patients presenting with dentinal hypersensitivity. In this study, a total of 25 patients with at least three teeth exhibiting dentin hypersensitivity (78 teeth in total) were assessed. Three groups were randomly assigned to receive different treatments for the teeth: Group 1 received D/Sense Crystal treatment, Group 2 received Fluorprotector vivampuole therapy, and Group 3 received Single Bond Universal dentin bonding agent. Using a visual analogue scale (VAS), dentin hypersensitivity levels were measured based on the patients’ reactions to touch, air blast, and cold water stimuli. Before and after treatment, at particular intervals (one, seven, fourteen, sixty, and ninety days), pain levels were noted.

 Results: Initially, the baseline sensitivity measurements were similar across the three groups (Group-1: 9.2 ± 0.35, Group-2: 8.8 ± 0.46, Group-3: 8.9 ± 0.39) with a non-significant p-value of 0.15. However, significant differences in sensitivity reduction were observed immediately after treatment, with Group-3 exhibiting the most substantial decrease (5.3 ± 0.43) and Group-2 showing a moderate reduction (6.5 ± 0.45) with a p-value of 0.03. Over the 1-week, 1-month, and 3-month follow-ups, although differences persisted, they were not statistically significant (p-values of 0.09, 0.12, and 0.45, respectively). This study underscores the variable impacts of the dental agents on sensitivity reduction, emphasizing the need to consider both short-term and long-term effects when assessing dental treatments.

Conclusion: To summarize, this clinical trial successfully showcased a considerable reduction in dentin hypersensitivity (DH) across all three groups, with no reported side effects. After a single direct topical treatment, the Single Bond Universal dentin bonding agent administration resulted in an initial decrease in DH. Notably, at the 3-month follow-up, comparable DH scores were observed among all three groups.